Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma

Yoon‐Koo Kang; Thomas Yau; J.-W. Park; Ho Yeong Lim; Tzu-Hsuan Lee; Shuntaro Obi; Stephen L. Chan; Shukui Qin; R.D. Kim; Michelle Casey; C. Chen; Helen Bhattacharyya; James A. Williams; Olga Valota; D. Chakrabarti; Masatoshi Kudo

doi:10.1093/annonc/mdv388

Related publications

Article2017

KEYNOTE-240: Randomized phase III study of pembrolizumab versus best supportive care for second-line advanced hepatocellular carcinoma.

Richard S. Finn, Stephen L. Chan, Andrew X. Zhu, Jennifer J. Knox, Ann‐Lii Cheng, Abby B. Siegel, Oliver Bautista, P.A. Watson, Masatoshi Kudo

Article2016

Pembrolizumab vs best supportive care for second-line advanced hepatocellular carcinoma: Randomized, phase 3 KEYNOTE-240 study

Richard S. Finn, Stephen L. Chan, Andrew X. Zhu, Jennifer J. Knox, Ann‐Lii Cheng, A.B. Siegel, O. Bautista, P.A. Watson, Masatoshi Kudo

Article2017

Phase 3, randomized KEYNOTE-240 study of pembrolizumab (Pembro) versus best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC)

Stephen L. Chan, Richard S. Finn, Andrew X. Zhu, Jennifer J. Knox, Ann‐Lii Cheng, A.B. Siegel, O. Bautista, Masatoshi Kudo

Article2014

Randomised Study of Axitinib (Axi) Plus Best Supportive Care (Bsc) Versus Placebo (Pbo) Plus Bsc in Patients with Advanced Hepatocellular Carcinoma (Hcc) Following Prior Antiangiogenic Therapy

Y-K. Kang, Thomas Yau, Jung‐Won Park, Éveline Boucher, Ho Yeong Lim, Ronnie T. P. Poon, T‐Y Lee, Shuntaro Obi, Sze Ling Chan, Shukui Qin, R.D. Kim, Jie Tang, Olga Valota, D. Chakrabarti, Masatoshi Kudo

Article2017

Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC): KEYNOTE-240.

Richard S. Finn, Stephen L. Chan, Andrew X. Zhu, Jennifer J. Knox, Ann‐Lii Cheng, Abby B. Siegel, Oliver Bautista, Masatoshi Kudo

Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma

Discussion(0)

Related publications

KEYNOTE-240: Randomized phase III study of pembrolizumab versus best supportive care for second-line advanced hepatocellular carcinoma.

Pembrolizumab vs best supportive care for second-line advanced hepatocellular carcinoma: Randomized, phase 3 KEYNOTE-240 study

Phase 3, randomized KEYNOTE-240 study of pembrolizumab (Pembro) versus best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC)

Randomised Study of Axitinib (Axi) Plus Best Supportive Care (Bsc) Versus Placebo (Pbo) Plus Bsc in Patients with Advanced Hepatocellular Carcinoma (Hcc) Following Prior Antiangiogenic Therapy

Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC): KEYNOTE-240.